Grant ID RP200432
Awarded On February 19, 2020
Title GD2 Expression and Response to Chemoimmunotherapy in Neuroblastoma
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization Texas Tech University Health Sciences Center
Principal Investigator/Program Director Charles Reynolds
Cancer Sites Brain and Other Nervous System
Contracted Amount $1,196,214*

*Pending contract negotiation

Lay Summary

High-risk neuroblastoma (NB) is a lethal childhood malignancy treated with an antibody called dinutuximab. Dinutuximab binds to a molecule found on neuroblastoma cells called GD2 and results in killing the tumor cells. About 1/2 of NB patients will relapse after initial therapy, and relapse is often treated with cancer chemotherapy drugs temozolomide (TMZ) + irinotecan (IRN) + dinutuximab. We have shown that dinutuximab can enhance the killing of NB tumors grown in special mice (i.e. patient-derived xenografts =PDXs) to TMZ + IRN. We will show that dinutuximab enhances activity of TMZ + IRN against tumors with high binding of dinutuximab (high GD2) but not those with low dinutuximab binding ...

Read More